Y-mAbs Therapeutics’ Earnings Call: Mixed Sentiment and Future Outlook

Y-Mabs Therapeutics ((YMAB)) has held its Q1 earnings call. Read on for the main highlights of the call.

Y-mAbs Therapeutics’ recent earnings call revealed a mixed sentiment, highlighting both positive developments and notable challenges. The company reported revenue growth in its DANYELZA product, especially internationally, and advancements in its Radiopharmaceutical segment. However, it also faced significant declines in U.S. revenues and reduced R&D expenses, painting a balanced picture of highs and lows.

DANYELZA Revenue Growth

DANYELZA’s net product revenues reached $20.9 million in the first quarter of 2025, marking an 8% increase from the same period in 2024. This growth was primarily driven by strong international sales, showcasing the product’s expanding global footprint.

Strong Financial Position

Y-mAbs Therapeutics maintains a robust financial position with $60.3 million in cash, which is expected to sustain the company into 2027. This financial stability provides a solid foundation for future operations and potential growth initiatives.

Ex-U.S. Revenue Surge

The company experienced a remarkable 816% increase in Ex-U.S. DANYELZA net product revenues, reaching $7.5 million. This surge was largely attributed to growth in Western Asia, Eastern Asia, and Latin America, highlighting the success of the named patient program.

Radiopharmaceutical R&D Progress

Significant progress was made in the Radiopharmaceutical business unit, with the first patient dosed in the CD38-SADA Phase I clinical trial and the completion of Part A of the GD2-SADA Phase I clinical trial. These advancements underscore the company’s commitment to innovation in this segment.

NCCN Guidelines Inclusion

DANYELZA, when combined with chemotherapy, was added to the NCCN guidelines for treating relapsed or refractory neuroblastoma. This inclusion is expected to enhance the product’s market position and credibility among healthcare providers.

U.S. Revenue Decline

Despite international success, U.S. net product revenues for DANYELZA decreased by 28% compared to the previous year. This decline was due to competitive pressures and changes in ordering patterns, posing a challenge for the company’s domestic market.

Research and Development Expense Reduction

Research and development expenses decreased by $1.9 million, reflecting the timing of clinical trial completions. This reduction may indicate a temporary slowdown in R&D activities, which could impact future innovation.

Guidance Indicates Potential Revenue Decline

Y-mAbs Therapeutics provided guidance for the second quarter of 2025, with expected total revenues between $17 million and $19 million. This suggests a potential decline compared to the first quarter, aligning with seasonal trends and market dynamics.

Forward-Looking Guidance

Looking ahead, Y-mAbs reiterated its full-year 2025 guidance, emphasizing its strong financial position and ongoing international growth. The company plans to update its Radiopharmaceutical pipeline and GD2-SADA Phase I trial data on May 28, which could provide further insights into its future trajectory.

In summary, Y-mAbs Therapeutics’ earnings call presented a mixed sentiment with both positive and challenging aspects. While international growth and financial stability are promising, the decline in U.S. revenues and reduced R&D expenses pose challenges. The company’s forward-looking guidance reflects cautious optimism, with expectations for continued international expansion and strategic advancements in its Radiopharmaceutical segment.